Corixa Timeline For Bexxar Data Response May Mean FDA Action by Year-End
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Corixa anticipates fulfilling FDA’s request for additional data on the non-Hodgkin’s lymphoma agent Bexxar within three months of the agency’s March 16 "complete review" letter, Corixa and marketing partner GlaxoSmithKline said.